Table 1 Details of FDA-approved immune checkpoint inhibitors and corresponding antibodies for immunohistochemical staining
Year | Drug | Target protein | Antibody | Threshold % | Cell type | Therapy type | |
|---|---|---|---|---|---|---|---|
NSCLC | 2015 | Pembrolizumab | PD-1 | 22C3 | 50 | TC | 2nd line |
NSCLC | 2016 | Pembrolizumab | PD-1 | 22C3 | 1 | TC | 2nd line |
NSCLC | 2016 | Pembrolizumab | PD-1 | 22C3 | 5 | TC | 1st line |
Bladder CA | 2016 | Atezolizumab | PD-L1 | SP142 | 10 | IC | 1st line |
Bladder CA | 2017 | Pembrolizumab | PD-1 | 22C3 | 5 | IC | 1st line |
Bladder CA | 2017 | Durvalumab | PD-L1 | SP2632 | 10 | IC+TC | 1st line |
Gastric CA | 2018 | Pembrolizumab | PD-1 | 22C3 | 1 | IC+TC | 3rdline |
Cervical CA | 2018 | Pembrolizumab | PD-1 | 22C3 | 1 | IC+TC | 2nd line |
Triple negative Breast CA | 2019 | Atezolizumab | PD-L1 | SP142 | 1 | IC | 1st line |
NSCLC (Metastatic) | 2020 | Atezolizumab. | PD-L1 | SP142 | TC:50 IC: 10 | IC+TC | 1st line |
NSCLC (metastatic) | 2020 | Nivolumab + ipilimumab | PD-L1 | 28-8 | 1 | TC | 1st line |